Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy
CONCLUSIONS: Patients with PD post anti-CD19 CAR T-cell therapy, particularly those exhibiting initial PD, have poor long-term outcomes. Patients receiving at least one anti-lymphoma therapy after PD had improved overall survival, although no single approach appeared to confer a survival benefit. Few enrolled onto a clinical trial or received an allogeneic HSCT. These data reinforce the need to both further improve the durable CR rate after CAR T-cell therapy and to develop effective strategies for those not achieving a CR.Figure 1DisclosuresGopal: Spectrum: Research Funding; Pfizer: Research Funding; BMS: Research Funding; Seattle Genetics: Consultancy, Research Funding; Merck: Research Funding; Takeda: Research Funding; Brim: Consultancy; Janssen: Consultancy, Research Funding; Asana: Consultancy; Gilead: Consultancy, Research Funding; Aptevo: Consultancy; Incyte: Consultancy; Teva: Research Funding. Maloney: Juno Therapeutics: Research Funding; Roche/Genentech: Honoraria; Janssen Scientific Affairs: Honoraria; Seattle Genetics: Honoraria; GlaxoSmithKline: Research Funding. Turtle: Caribou Biosciences: Consultancy; Adaptive Biotechnologies: Consultancy; Nektar Therapeutics: Consultancy, Research Funding; Bluebird Bio: Consultancy; Precision Biosciences: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Juno Therapeutics / Celgene: Consultancy, Patents & Royalties, Research Funding; Eureka Therapeutics: Equity Ownership, Membership on...
Source: Blood - Category: Hematology Authors: Chow, V. A., Gopal, A. K., Maloney, D. G., Turtle, C. J., Smith, S. D., Shadman, M., Cassaday, R. D., Till, B. G., Tseng, Y. D., Warren, E. H., Shustov, A. R., Menon, M. P., Kanan, S., Acharya, U. H., Mullane, E., Hannan, L. M., Voutsinas, J. M., Gooley, Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting Source Type: research
More News: AstraZeneca | Biotechnology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Employment | Genetics | Hodgkin's Disease | Immunotherapy | Lymphoma | Men | Merck | Pfizer | Pharmaceuticals | Revlimid | Rituxan | Stem Cell Therapy | Stem Cells | Study | Transplants | University of Washington